Home — Products — Monoclonal Antibodies
ProductMonoclonal Antibodies
Research and pre-clinical grade monoclonal antibodies for target validation, assay development and biosimilar reference work.
What you are buying
Antibody supply is rarely the hard part — consistency between lots is. Our mAbs are produced under process-controlled conditions and released against defined specifications, so the material you validate a method against is the material you receive six months later.
- Target validation and screening
- Biosimilar reference and comparability work
- Assay development and method qualification
- Immunoassay and diagnostic development
Therapeutic antibody programmes.
A growing pipeline of biosimilar and novel therapeutic monoclonal antibodies, developed on Theertha's mammalian expression and purification platforms.
Trastuzumab
Anti-HER2 therapeutic monoclonal antibody — in process development.
Pembrolizumab · biosimilar
Anti-PD-1 checkpoint inhibitor — preclinical stage.
Ustekinumab · biosimilar
Anti-IL-12/23 monoclonal antibody — clone development.
Dostarlimab · biosimilar
Recombinant anti-PD-1 antibody — clone development.
Ranibizumab · biosimilar
Anti-VEGF-A antibody fragment — clone ready.
Development stages reflect current technical progress and do not imply regulatory approval or commercial availability. See our full pipeline.
Concept to commercial.
We support antibody programmes across the full development journey — take one module or the whole chain.
Target & clone
Construct design, gene synthesis and mammalian cell-line development, with regulatory-ready documentation from day one.
Process development
Upstream and downstream development engineered for high titre and recovery, scaling predictably from bench to pilot.
Analytical & characterization
Method development, qualification and validation with orthogonal product characterization.
Formulation
Formulation and stability programmes that carry a candidate into pre-clinical and clinical supply.
Scale-up & technology transfer
Documentation-first transfer to your site or manufacturer, with comparability and bridging studies.
Toward clinical & commercial supply
A clear path toward clinical and commercial supply, supported through our CDMO/CRO capabilities and partners.
Every antibody, in detail.
A closer look at each programme in our monoclonal-antibody portfolio — its target, class and current development stage.
Trastuzumab
Anti-HER2 monoclonal antibody and the reference molecule for HER2-positive breast and gastric cancer. Theertha has taken Trastuzumab into process development — upstream and downstream unit operations are being optimised for titre, recovery and a comparability-ready quality profile on our mammalian platform.
Enquire about TrastuzumabPembrolizumab
Anti-PD-1 checkpoint inhibitor and one of the most widely used immuno-oncology antibodies. As a biosimilar candidate it sits at preclinical stage, with cell-line and early process work underway to establish a developable, comparable molecule.
Enquire about PembrolizumabUstekinumab
Anti-IL-12/23 antibody used across immunology indications including psoriasis and inflammatory bowel disease. The programme is in clone development — expression clones are being generated and screened for productivity and product quality.
Enquire about UstekinumabDostarlimab
Recombinant anti-PD-1 antibody. At clone development, Theertha is building the expression system and the early analytical package that will define comparability.
Enquire about DostarlimabRanibizumab
Anti-VEGF-A antibody fragment for ophthalmic indications. The programme is clone ready — a productive clone is established and it is positioned to enter process development.
Enquire about RanibizumabDevelopment stages reflect current technical progress and do not imply regulatory approval or commercial availability. Vial imagery is an illustrative representation of Theertha development material, not finished commercial product.
Other product lines.
Need a custom specification?
Most of what we supply is programme-specific. Send us the requirement and we will confirm feasibility, timeline and price.